Topic: Pharmaceutical Revenue

The pharmaceutical industry spends an estimated $9 billion to $20 billion annually on television advertising, representing a massive portion of legacy media revenue. Critics argue that this financial dependence prevents news networks from objectively covering health and drug safety issues. Robert F. Kennedy Jr. has signaled intentions to target both pharmaceutical and junk food advertising as part of his health policy.

Pfizer is projected to earn $26 billion in 2021 from COVID-19 vaccines after a $4 billion first quarter. President Joe Biden is criticized for a verbal gaffe where he directed citizens to "vaccines dot gum" instead of vaccines.gov. The hosts argue that mainstream media has shifted from medical reporting to pure pharmaceutical marketing.

A theory is proposed that pharmaceutical companies are shifting toward a recurring revenue model by normalizing the need for annual COVID-19 shots. Additionally, the discussion suggests that the "variant" narrative serves as a convenient explanation or "backstop" for health officials if the initial vaccine rollout fails to prevent infections.

A comparison of television advertisements for Celebrex and Cymbalta focuses on the increasingly dire side effects listed in the disclaimers. The hosts note that Celebrex now explicitly mentions the risk of death, while Cymbalta lists suicidal thoughts and liver failure. They track the annual revenue of both drugs to see if "scarier" ads correlate with higher sales.

A comparison of commercials for Celebrex and Cymbalta reveals a trend of increasingly severe side effect warnings, including the explicit mention of death. Despite the warnings, both drugs generate billions in annual revenue, supporting a theory that "scary" side effects do not deter sales.